Investigational drug · Phase 3
LYB005
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus (RSV) Infection, RSV Vaccine.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "LYB005"
First trial start
2026
Nov 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LYB005", any sponsor or status.
Conditions studied
As listed on its trial records.
- Respiratory Syncytial Virus (RSV)
- Respiratory Syncytial Virus (RSV) Infection
- RSV Vaccine
Approved drugs for the same conditions: RSV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "LYB005" as an intervention, largest first.
- A Study to Evaluate Efficacy, Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and OlderPivotal-lookingNot yet recruiting
Guangzhou Patronus Biotech Co., Ltd.Industry
NCT07908654 · 25,000 participants (planned) · Start Nov 2026 · Primary completion Sep 2027
Drug: LYB005; Placebo · For: Respiratory Syncytial Virus (RSV); Respiratory Syncytial Virus (RSV) Infection; RSV Vaccine
Sites: Nanjing, China
- A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and OlderPivotal-lookingActive, not recruiting
Guangzhou Patronus Biotech Co., Ltd.Industry
NCT07208461 · 700 participants (planned) · Start Oct 21, 2025 · Primary completion Mar 2026
Drug: Low dose antigen of LYB005 without A01B adjuvant; Low dose antigen of LYB005 with A01B adjuvant and 5 more · For: Respiratory Syncytial Virus Infection Prevention
Sites: Dangyang, China
- Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and OlderActive, not recruiting
Guangzhou Patronus Biotech Co., Ltd.Industry
NCT06904222 · 90 participants (planned) · Start Apr 15, 2025 · Primary completion Aug 2026
Drug: Low dose antigen of LYB005 without A01B adjuvant; Low dose antigen of LYB005 with A01B adjuvant and 5 more · For: Respiratory Syncytial Virus Infection
Sites: Dangyang, China
- A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy AdultsActive, not recruiting
Guangzhou Patronus Biotech Co., Ltd.Industry
NCT06442241 · 84 participants (planned) · Start Jul 31, 2024 · Primary completion Dec 30, 2025
Drug: LYB005 low dose without adjuvant; LYB005 middle dose without adjuvant and 6 more · For: Respiratory Syncytial Virus (RSV); RSV Infection
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Respiratory Syncytial Virus (RSV)
- CHO Cellrecombinant zoster vaccine, Recombinant Respiratory Syncytial Virus VaccinePhase 39 trials
MAXVAX Biotechnology Limited Liability Company · Herpes Zoster, Respiratory Syncytial Virus (RSV), Herpes Zoster (HZ)
- RSVpreFRESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, PF-06928316Phase 38 trials
Pfizer · Respiratory Syncytial Virus (RSV), Lower Respiratory Tract Illness, Adult
- RSVpreF VaccinePhase 33 trials
Pfizer · Respiratory Syncytial Virus, Respiratory Syncytial Virus (RSV)
- su vaccineRZVPhase 32 trials
GSK · Herpes Zoster, Respiratory Syncytial Virus (RSV)
- zelicapavirPhase 32 trials
Enanta Pharmaceuticals, Inc · RSV, RSV Infection, Respiratory Syncytial Virus (RSV)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.